Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kineret (anakinra) for Bladder Pain Syndrome
2021-003683-28Phase 2Active
- Sponsor
- SelectImmune Pharma
- Start
- Jan 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of anakinra in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS), sponsored by SelectImmune Pharma. Primary endpoint: Symptom reduction by O'Leary score. Started Jan 2022; status: active.
02
Drugs
anakinra
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on 2021-003683-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003683-28.